<DOC>
	<DOCNO>NCT02179372</DOCNO>
	<brief_summary>The aim study test Eicosapentaenoic free fatty acid 's effect calprotectin level IBD patient clinical remission . During study fecal calprotectin level measure every 3 month clinical flare register .</brief_summary>
	<brief_title>Eicosapentaenoic Free Fatty Acid Fecal Calprotectin Inflammatory Bowel Diseases</brief_title>
	<detailed_description />
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Age range between18 80 year . Patients Ulcerative Colitis ( diagnosed base clinic , endoscopic histologic criterion ) clinical remission ( SCCAI = 0 ) least 3 month stable therapy ( without therapeutic modification three previous month ) 5ASA , immunomodulators and/or biologics . Patients affect Crohn 's Disease ( diagnosed base clinic , endoscopic histologic criterion ) ) clinical remission ( CDAI &lt; 150 ) least 3 month stable therapy ( without therapeutic modification three previous month ) 5ASA , immunomodulators and/or biologics . Fecal calprotectin baseline &gt; 150 μg/g . Patients affect Ulcerative Colitis Crohn 's Disease respectively SCCAI ≥ 1 CDAI ≥150 . Patients steroid therapy . Patients therapy wih warfarin anticoagulant . Known suppose ipersensitivity eicosapentaenoic acid/omega 3 . Women fertile age refuse use contracceptives specify study ( oral contraception , IUD ) breastfeed woman . Patients severe clinical condition investigator consider controindicate patient partecipation study . Therapy modification and/or assumption sperimental therapy within three month study inclusion . Patients unable follow protocol procedure sign informate consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>